Shield Therapeutics announces Board member Hans Peter Hasler as next Non-Executive Chairman

– UK, London –  Shield Therapeutics plc (LON: STX), a commercial-stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru/Accrufer, today announced the appointment of Hans Peter Hasler as non-executive Chairman of the Company with effect from the Annual General Meeting on 18 June 2020.

 “I am very pleased to see Hans Peter appointed as our Chairman. I have worked increasingly closely with Hans Peter over the last two years and value his experience and insights and the support he has given me personally.” said Tim Watts, CEO.

As announced on 21 May 2020, James Karis, the current Chairman, informed the Company that he would not seek re-election and would be stepping down at the AGM on 18 June 2020. Hans Peter Hasler has therefore been appointed with effect from the AGM.

About Hans Peter Hasler

Hans Peter joined Shield’s Board of Directors in July 2018 and has served as Chairman of the Nomination Committee and a member of the Audit Committee. Hans Peter has prior executive experience including as Chief Operating Officer at both Elan Corporation and Biogen Inc. as well as Chief Marketing Officer of Wyeth Pharmaceuticals, Radnor, PA. He is non-executive Chairman of the Board of HBM Healthcare Investments AG, Zug/Switzerland and a non-executive director of Minerva Neuroscience Inc., Boston.

Hans Peter Hasler said: “I am delighted to have been appointed as Chairman of Shield at a critical time for the Group. Feraccru/ Accrufer is an excellent product with enormous potential and I look forward to continuing to help the Group find ways of making it available to the widest possible number of patients and to translating that into value for shareholders. I also look forward to working with the rest of the Board and the management team in these endeavours.”

About Shield Therapeutics plc

Shield is a de-risked, commercial-stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients’ unmet medical needs. The Company’s clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives. The Group’s lead product, Feraccru/ Accrufer has exclusive IP rights until the mid-2030s and is approved for the treatment of iron deficiency with or without anaemia in adults in the European Union, the United States and Switzerland. In Europe, it is marketed as Feraccru with commercialisation led by Norgine BV and in the USA the product will be marketed as Accrufer with Shield currently in the process of selecting a commercialisation partner. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co. Ltd for the development and commercialisation of Feraccru/Accrufer in China, Hong Kong, Macau and Taiwan.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.